Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents

被引:74
作者
Leadley, RJ
Chi, LG
Rebello, SS
Gagnon, A
机构
[1] Pfizer Inc, Global Res & Dev, Ann Arbor Labs, Cardiovasc Therapeut, Ann Arbor, MI 48105 USA
[2] Aventis Pharmaceut, Bridgewater, NJ 08807 USA
关键词
thrombosis; in vivo; animal models; anti-thrombotics; Factor Xa;
D O I
10.1016/S1056-8719(00)00095-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiovascular and cerebrovascular diseases continue to be the leading cause of death throughout the world. Over the past two decades, great advances have been made in the pharmacological treatment and prevention of thrombotic disorders (e.g., tissue plasminogen activators, platelet GPIIb/IIIa antagonists, ADP receptor antagonists such as clopidogrel, low-molecular weight heparins, and direct thrombin inhibitors). New research is leading to the next generation of antithrombotic compounds such as direct coagulation FVIIa inhibitors, tissue factor pathway inhibitors, gene therapy, and orally active direct thrombin inhibitors and coagulation Factor Xa (FXa) inhibitors. Animal models of thrombosis have played a crucial role in discovering and validating novel drug targets, selecting new agents for clinical evaluation, and providing dosing and safety information for clinical trials. In addition, these models have provided valuable information regarding the mechanisms of these new agents and the interactions between antithrombotic agents that work by different mechanisms. This review briefly presents the pivitol preclinical studies that led to the development of drugs that have proven to be effective clinically. The role that animal models of thrombosis are playing in the discovery and development of novel antithrombotic agents is also described, with specific emphasis on FXa inhibitors. The major issues regarding the use of animal models of thrombosis, such as the use of positive controls, appropriate pharmacodynamic markers of activity, safety evaluation, species-specificity, and pharmacokinetics, are highlighted. Finally, the use of genetic models in thrombosis/hemostasis research and pharmacology is presented using gene-therapy for hemophilia as an example of how animal models have aided in the development of these therapies that are now being evaluated clinically. In summary, animal models have contributed greatly to the discovery of currently available antithrombotic agents and will play a primary role in the discovery and characterization of the novel antithrombotic agents that will provide safe and effective pharmacological treatment for life-threatening thrombotic diseases. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:101 / 116
页数:16
相关论文
共 133 条
[1]  
AGNELLI G, 1990, THROMB HAEMOSTASIS, V63, P204
[2]  
ANDERSON HV, 1994, THROMBOSIS HEMORRHAG, P385
[3]   HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL [J].
ANTMAN, EM .
CIRCULATION, 1994, 90 (04) :1624-1630
[4]   Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].
Antman, EM .
CIRCULATION, 1996, 94 (05) :911-921
[6]  
Badimon L, 1997, THROMB HAEMOSTASIS, V78, P667
[7]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[8]   LACK OF USEFULNESS OF PROLONGED BLEEDING TIMES IN PREDICTING HEMORRHAGIC EVENTS IN PATIENTS RECEIVING THE 7E3 GLYCOPROTEIN IIB/IIIA PLATELET ANTIBODY [J].
BERNARDI, MM ;
CALIFF, RM ;
KLEIMAN, N ;
ELLIS, SG ;
TOPOL, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (15) :1121-1125
[9]   Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies [J].
Bi, L ;
Sarkar, R ;
Naas, T ;
Lawler, AM ;
Pain, J ;
Shumaker, SL ;
Bedian, V ;
Kazazian, HH .
BLOOD, 1996, 88 (09) :3446-3450
[10]  
BICK RL, 1995, CLIN LAB MED, V15, P1